Curcumin treatment of chronic myelogenous leukaemia (CML) cells resulted in a dose-dependent rise in phosphatase and tensin homolog (PTEN), the miR-21 target. The gene discussed is PTEN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.